« Resveratrol (SRT501): Development Halted |
| Novartis, Meet Novartis (Job Cuts or Not?) »
December 1, 2010
The Sames-Sezen Case: The Feds Speak
Paul Bracher at Chembark broke the news that the Office of Research Integrity has issued a finding on the Sames-Sezen misconduct case at Columbia. This was big news back in 2006 and 2007, and it should still be news now.
For those who haven't followed this, the case concerns a series of papers published from Dalibor Sames' lab at that university on some interesting C-H activation chemistry. This work was largely performed by a graduate student, Bengü Sezen, but none of it has proven to be reproducible, and there was a string of retractions. (Sezen herself maintained that there were no problems with the work). So far, so bad - but what gives the story more depth is that papers were retracted where Sezen was not even a co-author and the apportionment of blame is still very much arguable. That last point gets into a lot of speculation, but the investigations into the matter haven't done much to clear any of it up.
Here's a PDF with some more background for those wanting to get up to speed, and Paul's earlier posts on the matter have a lot of information for those wanted to dig into this case. I'm not sure that we're ever going to know what really happened here, which is a shame, because we'd all like for it not to happen again.
+ TrackBacks (0) | Category: The Dark Side
POST A COMMENT
- RELATED ENTRIES
- A Last Summer Day Off
- The Early FDA
- Drug Repurposing
- The Smallest Drugs
- Life Is Too Short For Some Journal Feeds
- A New Look at Phenotypic Screening
- Small Molecules - Really, Really Small
- InterMune Bought